Items tagged with Treatment
Effect of high-dose rifapentine on efavirenz pharmacokinetics in HIV/TB coinfection (post)
Results of a phase 3 randomized trial found that daily treatment with high-dose rifapentine for tuberculosis (TB) infection decreased efavirenz clearance and achieved therapeutic targets among patients coinfected with HIV receiving efavirenz-based antiretroviral therapy (ART). These findings were published in Clinical Infectious Diseases.
High-dose rifamycin vs standard-dose rifamycin in individuals with TB (post)
Treatment with high-dose rifamycin (HDR)-based regimens was not associated with an increased risk for severe adverse events (SAE) compared with standard-dose rifamycin (SDR)-based regimens among patients with tuberculosis (TB) infection, according to results of a study published in Thorax.
CROI 2022: Fewer pills plus shorter time: New way to control drug-resistant TB? (post)
Three investigational drug regimens to treat drug-resistant tuberculosis (TB) were superior to standard of care, with fewer unfavorable outcomes and a shorter treatment time, a researcher said.
CDC recommends 4-month regimen for drug-susceptible TB (post)
The CDC published a recommendation and interim guidance in MMWR for a 4-month regimen to treat patients aged 12 years or older with drug-susceptible pulmonary tuberculosis.
Treatment length reduced for children with TB (post)
A UCL-led international trial exploring the effectiveness of tuberculosis (TB) treatment in children has led to a change in the World Health Organisation’s global guidelines for managing the disease.
Higher dose antibiotic shown safe in TB patients likely more effective in treating deadliest form of TB (post)
A Johns Hopkins Children’s Center-led study in animals suggests that high doses of a widely used antibiotic called rifampin may safely treat and reduce the duration of treatment for the deadliest form of tuberculosis that affects the brain, potentially improving survival rates for patients and decreasing the likelihood of lasting adverse effects of the disease. Additional studies in a small number of people also shed light on how rifampin moves through the body, including into the brain, and how rifampin levels could change during treatments, showing how the research could potentially translate to humans.
CROI 2022 TB round up (post)
Treatment Action Group (TAG) released an overview of TB data reported at the 29th Conference on Retroviruses and Opportunistic Infections (CROI 2022) held virtually on 12-16 February 2022. A summary of major findings and TAG’s take on them are available here.
Managing drug interactions in HIV and TB coinfection is complex (post)
Tuberculosis (TB) is a serious health concern, especially when coupled with HIV. Individuals with HIV are more likely to become sick if they are coinfected with TB. Infections among individuals with TB include those in the following categories:
‘Test and treat’ is being used to tackle HIV. Why not TB? (post)
Worldwide, tuberculosis (TB) remains a significant cause of disease and deaths. Around 9.9 million people had the disease in 2020. The burden is higher in low- and middle-income countries. Africa accounts for 25% of TB cases.
Outcomes of concomitant bedaquiline and delamanid in patients with multidrug-resistant TB (post)
Concomitant treatment with bedaquiline and delamanid (Bdq-Dlm) was determined to be safe and effective and did not increase the risk for cardiotoxicity in patients with multidrug- and rifampicin-resistant (MDR/RR) tuberculosis (TB) infection, according to results of a study published in Clinical Infectious Diseases.
Page 62 of 108 · Total posts: 0
←First 61 62 63 Last→